Association of dyslipidemia and systematic inflammation with renal cell carcinoma bone metastasis

黄子雄,杜依青,张晓鹏,刘士军,徐涛
DOI: https://doi.org/10.3760/cma.j.cn112330-20191211-00550
2020-01-01
Abstract:Objective:To investigate if lipid metabolism or systematic inflammation played roles in RCC bone metastasis (RCC-BM).Methods:A series of 239 RCC patients from Peking University People's Hospital between Nov. 2009 and Nov. 2017 was retrospectively reviewed. Sixty-eight patients had RCC-BM in which 56 had synchronal and 12 had metachronous metastasis (RCC-BM group). The other 171 patients without any metastasis were set as control group. The baseline age was (59.47±11.41) years in RCC-BM group and (58.61±11.10) years in control group ( P>0.05). There were 53 males and 15 females in RCC-BM group, 116 males and 55 females in control group ( P>0.05). Somking history (72.1% in RCC-BM group, 69.6% in control group) and concomitant hypertension (60.3% in RCC-BM group, 53.8% in control group), diabetes mellitus (82.4% in RCC-BM group, 80.7% in control group) were comparable between two groups ( P>0.05). Significantly lower body mass index [BMI, (24.25±4.00) kg/m 2]was found in RCC-BM group comparing to that in control group [(25.41±3.67) kg/m 2]( P<0.05). RCC stages in RCC-BM group: T 1 29 cases, T 2 7 cases, T 3 18 cases, T 4 13 cases; RCC stages in control group: T 1 128 cases, T 2 8 cases, T 3 29 cases, T 4 6 cases. Preoperative serum lipid profiles (total triglyceride/TG, total cholesterol/TC, low density lipoprotein cholesterol/LDL-C, high density lipoprotein cholesterol/HDL-C levels) were collected. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were calculated as inflammatory parameters. Binary multivariate logistic regression and univariate analysis ( t test, chi-squared test) were performed. Results:Significantly increasing LDL-C levels [(2.89±0.76)mmol/L] were found among RCC-BM patients comparing to non-metastatic RCC control patients [(2.61±0.81)mmol/L, P<0.05]. NLR (3.74±2.23 in RCC-BM group, 2.23±1.68 in control group) and PLR(193.88±139.43 in RCC-BM group, 122.67±54.66 in control group) significantly elevated in RCC-BM group ( P<0.001). Serum LDL-C level was determined to increase hazard ratios of progressing RCC-BM after balancing baseline features, T stages and histological sub-types ( HR=1.766, 95% CI 1.025-3.043, P<0.05). Patients with high NLR (>3) had higher risk of developing RCC-BM ( HR=5.052, 95% CI 1.987-12.845, P<0.05). Ratio of patients with high LDL-C (≥2.58 mmol/L, 69.2%, 45 cases) was also greater in RCC-BM group (47.4%, 81 cases, P<0.01). Conclusions:This study suggests dyslipidemia is associated with RCC-BM. Systematic inflammation is also involved in. LDL-C and NLR could be utilized as predictors to identify high-risk patients to develop RCC-BM.
What problem does this paper attempt to address?